EE130 Cost-Utility of Cabonivo vs Sunitinib, Pazopanib and Ipinivo for First Line Advanced Renal-Cell Carcinoma in the Private Healthcare System in Brazil

Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.382
https://www.valueinhealthjournal.com/article/S1098-3015(22)02586-4/fulltext
Section Title :
Section Order : 12185
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02586-4&doi=10.1016/j.jval.2022.09.382
HEOR Topics :
Tags :
Regions :